lirequinil lirequinil lirequinil (ro41-3696) is a nonbenzodiazepine hypnotic drug which binds to benzodiazepine sites on the gabaa receptor. in human clinical trials, lirequinil was found to have similar efficacy to zolpidem, with less side effects such as clumsiness and memory impairment. however it was also much slower acting than zolpidem, with peak plasma concentrations not reached until 2.5 hours after oral administration, and its o-desethyl metabolite ro41-3290 is also active with a half-life of 8 hours. this meant that while effective as a hypnotic, lirequinil failed to prove superior to zolpidem due to producing more next-day sedation, and it has not been adopted for clinical use. it was developed by a team at hoffmann-la roche in the 1990s. active metabolite ro41-3290 lirequinilclinical dataatc codenoneidentifiers iupac name 10-chloro-1--3-phenyl-6,7-dihydrobenzoquinolizin-4-one cas number143943-73-1 ypubchem cid3045375chemspider2308119 nunii2vuw1087adchemblchembl2105118comptox dashboard (epa)dtxsid80162579 chemical and physical dataformulac26h25cln2o3molar mass448.95 g·mol−13d model (jsmol)interactive image smiles cco1ccn(c1)c(=o)c2=c3c4=c(ccn3c(=o)c(=c2)c5=cc=cc=c5)c=cc(=c4)cl inchi inchi=1s/c26h25cln2o3/c1-2-32-20-11-12-28(16-20)25(30)23-15-22(17-6-4-3-5-7-17)26(31)29-13-10-18-8-9-19(27)14-21(18)24(23)29/h3-9,14-15,20h,2,10-13,16h2,1h3/t20-/m0/s1 nkey:cbswrauyciiuei-fqevstjzsa-n n ny (what is this?) (verify)